Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine Cessation in Long-term Parkinson's Disease
NCT04260581Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amantadine in Parkinson's disease (PD), sponsored by Seoul National University Hospital. Primary endpoint: Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III at 8 weeks. Status: unknown.
02
Drugs
amantadine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04260581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260581.